Description de l'entreprise
Ryvu Therapeutics is developing therapeutics that address clinical limitations of current treatments in oncolog.
Their lead candidate, RVU120, is a selective CDK8/CDK19 kinase inhibitor with potential for development in hematological malignancies and solid tumors, currently in Phase 1b study for the treatment of acute myeloid leukemia and myelodysplastic syndrome, and Phase I/II for the treatment of r/r metastatic or advanced solid tumors. SEL24 (MEN1703) is a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group, in Phase 2 clinical development for the treatment of acute myeloid leukemia.
Conseil d'administration & Conseil de surveillance
| PDG |
| Paweł Przewięźlikowski |
| Conseil d'administration |
| Vatnak Vat-Ho, Hendrik Nogai, Kamil Sitarz, Krzysztof Brzózka |
| Conseil de surveillance |
| Piotr Romanowski, Tadeusz Wesołowski, Rafał Chwast, Axel Glasmacher, Jarl Jungnelius, Thomas Turalski |
Données de l'entreprise
| Nom: |
RYVU THERAPEUTICS S.A. |
| Adresse: |
Leona Henryka Sternbacha 2,30-394 Kraków |
| Téléphone: |
+48 12 314 02 00 |
| Fax: |
+48 12 297 47 01 |
| Courriel: |
ryvu@ryvu.com
|
| Internet: |
https://ryvu.com/ |
| Industrie: |
Biotechnology |
| Secteur: |
Biotechnology |
| Sous-secteur: |
- |
| Fin de l'exercice financier: |
31/12 |
| Flotte libre: |
74.30% |
| IPO date: |
14/07/2011 |
Relations avec les investisseurs
| Nom: |
- |
| Téléphone IR: |
- |
| IR-Fax: |
- |
| E-mail IR: |
ir@ryvu.com
|
